Idarubicin (HCl)

Drug #1302

Idarubicin (HCl) is antineoplastic agent or anticancer drug. Idarubicin (HCl) is a synthetic analog of anthracycline daunorubicin. Idarubicin differ from daunorubicin by the absence of methoxy group at the C-4 position. Idarubicin (HCl) is effective in the treatment of different types of cancers. Idarubicin (HCl) is used in combination of other anticancer drugs to obtain best therapeutic effects and to reduce toxicity or side effects. It has less potentially less cardiotoxicity than doxorubicin and daunorubicin.Idarubicin (HCl) is administered orally or intravenously.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Anthracycline.

Molecular Weight: 534 · Solubility in Water: sparingly soluble · Solubility in Alcohol: slightly soluble · Non-proprietary name: Idarubicin (HCl) · pH: 5.

Pharmacokinetics

Absorption: Idarubicin (HCl) has an oral bioavailability is 37.5% (±12.5%).

Distribution: Idarubicin (HCl) has a volume of distribution is 1530-1700 l/square meter. plasma protein binding is 97% & active metabolite 94%.

Elimination: it is metabolised via both hepatic & extrapepatic, plasma half-life is 20-22 hr, renal excretion is <5.

Indications

Idarubicin (HCl) is primarily indicated in conditions like Acute erythroleukemia, Acute myelogenous leukemia, Acute non-lymphoblastic leukemia, Acute non-lymphocytic leukaemia, Acute promyelocytic leukemia, Advanced breast cancer, Advanced breast or prostate cancer.

Idarubicin (HCl) is also indicated for secondary conditions like Breast cancer, Multiple myeloma, Non-hodgkin's lymphoma, Non-hodgkin's lymphoma.

Contraindications

Idarubicin (HCl) is contraindicated in conditions like Bone marrow suppression.

Dosage

Idarubicin (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
30 mg/m2	30 mg/m2	Every 24h		Daily for 3 day for leukemia.
45 mg/m2	45 mg/m2	Every 24h		For reftractory breast cancer.
12 mg/m sq.	12 mg/m sq.	Every 24h	Slow IV	Over 10-15 minutes.
Paediatric Dosage (20kg)
45 mg/m2	45 mg/m2	—		For 3 days.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Idarubicin (HCl) in overdosage may give rise to further complications which include Urticaria , Neutropenia , Seizures , Cardiomyopathy , Pancytopenia , Leukopenia.

Idarubicin (HCl) produces potentially life-threatening effects which include Congestive heart failure, Myelosuppression , Fatal arrhythmias. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Idarubicin (HCl) are Arrhythmias.

Idarubicin (HCl) is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Alopecia, Anemia, Bullous rash, Cardiac arrhythmias , Diarrhea, Discoloration of urine, Mucositis, Nausea, Sinus tachycardia, StomatitisX, Supraventricular tachycardia, Vomiting .

Warnings / Precautions

Idarubicin is not recommended for use during pregnancy or lactation. It should be used with caution in patients with any pre-existing liver disease, kidney disease, heart disease, blood disorders or any allergy. Therapy should not be initiated until patient recover normal hematopoiesis after bone merrow depression. It should be used with caution in patient with dental diseases. IM injection should not be administered to the patients receiving idarubicin.

Interference in Pathology

Idarubicin (HCl) may interfere in the diagnosis of Liver Function Test (LFT) .

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

10 mg 10 mg/ml 5 mg

Storage Conditions

Idarubicin (HCl) should be stored Inj (reconstituted soln).

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs

Manufacturers

Manufacturers of Idarubicin (HCl) in Pakistan:

Al-Habib Pfizer